Peer-reviewed veterinary case report
Outcomes for dogs after surgery for high-grade skin mast cell tumors
By Moore, Antony S et al.·Published in Veterinary and comparative oncology·2020·Veterinary Oncology Consultants, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Retrospective outcome evaluation for dogs with surgically excised, solitary Kiupel high-grade, cutaneous mast cell tumours.
- Species:
- dog
Plain-English summary
A group of 49 dogs with high-grade skin tumors called mast cell tumors (MCTs) underwent surgery to remove their tumors. The dogs had a good chance of survival, with a median survival time of about 2.8 years after surgery. However, some dogs faced complications, such as local tumor recurrence or new tumors developing. The study found that dogs with smaller tumors and lower cell division rates (mitotic counts) tended to live longer. Overall, while many dogs did well after surgery, those with more aggressive tumors had a shorter survival time.
People also search for: dog mast cell tumor prognosis · high-grade mast cell tumor treatment · dog skin tumor survival rate
Abstract
Published outcomes for dogs with specifically high-grade mast cell tumours (MCTs), controlled for clinical stage, are few. Clinical outcomes for 49 dogs with Kiupel high-grade, clinical stage I, cutaneous MCTs were evaluated. Median survival time (MST) was 1046 days; 1 and 2-year survival rates were 79.3% and 72.9%, respectively. At study end 24 dogs had died, 23 dogs were alive (median follow-up 980 days) and 2 dogs were lost to follow-up. Death was considered MCT-related in 14 of 20 dogs with a known cause of death. Local tumour recurrence developed in nine dogs (18.4%); regional lymph node metastasis occurred in six dogs (12.2%); and a new MCT developed in 15 dogs (30.1%). Tumour location, histologic margin size and use of chemotherapy did not affect MST; increasing mitotic count (P = .001) and increasing tumour diameter (P = .024) were independently negatively prognostic. Six dogs that developed lymph node metastasis after surgery had worse MST (451 days) than 42 dogs that did not develop metastasis (1645 days); (P < .001). Our study suggests that dogs with local surgical control of clinical stage I histologically high Kiupel grade cutaneous MCT may have a long survival time; especially those with smaller tumours and a lower mitotic count. Our results suggest that evaluation of staging information and mitotic count may be equally helpful as histologic grading when making a prognosis; and highlight the importance of not relying on histologic grade alone when predicting survival for dogs with MCT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31916687/